vs
Side-by-side financial comparison of Soho House & Co Inc. (SHCO) and Bio-Techne (TECH). Click either name above to swap in a different company.
Soho House & Co Inc. is the larger business by last-quarter revenue ($370.8M vs $311.4M, roughly 1.2× Bio-Techne). Bio-Techne runs the higher net margin — 16.4% vs -5.0%, a 21.4% gap on every dollar of revenue. On growth, Soho House & Co Inc. posted the faster year-over-year revenue change (11.2% vs -1.5%). Over the past eight quarters, Soho House & Co Inc.'s revenue compounded faster (13.5% CAGR vs 1.3%).
Soho House is an international private members’ club with a focus on the media, arts and fashion industries.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SHCO vs TECH — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $370.8M | $311.4M |
| Net Profit | $-18.7M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | -1.6% | 24.2% |
| Net Margin | -5.0% | 16.4% |
| Revenue YoY | 11.2% | -1.5% |
| Net Profit YoY | -10790.3% | 126.0% |
| EPS (diluted) | $-0.10 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | — | $295.9M | ||
| Q3 25 | $370.8M | — | ||
| Q2 25 | $329.8M | $317.0M | ||
| Q1 25 | $282.9M | $316.2M | ||
| Q4 24 | $305.6M | $297.0M | ||
| Q3 24 | $333.4M | $289.5M | ||
| Q2 24 | $302.9M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-18.7M | — | ||
| Q2 25 | $24.9M | $-17.7M | ||
| Q1 25 | $8.2M | $22.6M | ||
| Q4 24 | $-91.7M | $34.9M | ||
| Q3 24 | $175.0K | $33.6M | ||
| Q2 24 | $-29.9M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | -1.6% | — | ||
| Q2 25 | 18.1% | -7.5% | ||
| Q1 25 | 12.3% | 12.2% | ||
| Q4 24 | -23.1% | 16.0% | ||
| Q3 24 | 11.4% | 13.8% | ||
| Q2 24 | -4.3% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -5.0% | — | ||
| Q2 25 | 7.5% | -5.6% | ||
| Q1 25 | 2.9% | 7.1% | ||
| Q4 24 | -30.0% | 11.7% | ||
| Q3 24 | 0.1% | 11.6% | ||
| Q2 24 | -9.9% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $0.13 | $-0.11 | ||
| Q1 25 | $0.04 | $0.14 | ||
| Q4 24 | $-0.48 | $0.22 | ||
| Q3 24 | $0.00 | $0.21 | ||
| Q2 24 | $-0.15 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $142.5M | $209.8M |
| Total DebtLower is stronger | $735.8M | — |
| Stockholders' EquityBook value | $-351.6M | $2.1B |
| Total Assets | $2.7B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | $142.5M | — | ||
| Q2 25 | $150.3M | $162.2M | ||
| Q1 25 | $150.1M | $140.7M | ||
| Q4 24 | $152.7M | $177.5M | ||
| Q3 24 | $142.8M | $187.5M | ||
| Q2 24 | $148.5M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | $735.8M | — | ||
| Q2 25 | $729.8M | $346.0M | ||
| Q1 25 | $705.1M | $330.0M | ||
| Q4 24 | $691.5M | $300.0M | ||
| Q3 24 | $694.8M | $300.0M | ||
| Q2 24 | $682.1M | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | $-351.6M | — | ||
| Q2 25 | $-348.6M | $1.9B | ||
| Q1 25 | $-340.1M | $2.0B | ||
| Q4 24 | $-335.1M | $2.1B | ||
| Q3 24 | $-279.4M | $2.1B | ||
| Q2 24 | $-231.7M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.5B | $2.6B | ||
| Q4 24 | $2.4B | $2.7B | ||
| Q3 24 | $2.6B | $2.7B | ||
| Q2 24 | $2.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.9M | — |
| Free Cash FlowOCF − Capex | $3.5M | — |
| FCF MarginFCF / Revenue | 0.9% | — |
| Capex IntensityCapex / Revenue | 8.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $34.9M | — | ||
| Q2 25 | $41.0M | $98.2M | ||
| Q1 25 | $22.8M | $41.1M | ||
| Q4 24 | $26.9M | $84.3M | ||
| Q3 24 | $20.6M | $63.9M | ||
| Q2 24 | $36.0M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $12.4M | $93.3M | ||
| Q1 25 | $7.5M | $31.0M | ||
| Q4 24 | $18.5M | $77.5M | ||
| Q3 24 | $10.3M | $54.7M | ||
| Q2 24 | $10.2M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 3.8% | 29.4% | ||
| Q1 25 | 2.7% | 9.8% | ||
| Q4 24 | 6.1% | 26.1% | ||
| Q3 24 | 3.1% | 18.9% | ||
| Q2 24 | 3.4% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.5% | — | ||
| Q2 25 | 8.7% | 1.5% | ||
| Q1 25 | 5.4% | 3.2% | ||
| Q4 24 | 2.7% | 2.3% | ||
| Q3 24 | 3.1% | 3.2% | ||
| Q2 24 | 8.5% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 2.79× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 117.70× | 1.90× | ||
| Q2 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SHCO
| Membership | $122.7M | 33% |
| Other | $122.0M | 33% |
| Membership Revenue | $58.5M | 16% |
| Other Revenue | $28.5M | 8% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $24.8M | 7% |
| Elimination Of Equity Accounted Revenue | $13.4M | 4% |
| Related Party | $2.0M | 1% |
| Soho House | $1.0M | 0% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
